Adynxx Inc (ADYX)
Adynxx, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing transcription factor decoy technologies for pain and inflammatory diseases. Its AYX platform includes brivoligide, which is being studied in Phase II development for reducing postoperative pain, as well as AYX2, a pre-clinical candidate being evaluated for focal chronic pain. Founded in 2007, the company is headquartered in San Francisco, California. Adynxx’s common stock trades on OTC Markets under the symbol ADYX.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Analyst Price Target | Analyst Target Upside/Downside | Overall Financial Health | Dividend Yield | Market Cap |
|---|---|---|---|---|---|---|
|
OTC-ADYX
|
Not available
|
Not available
|
Not available
|
Good
|
0.0%
|
0.58 K
|